Nose to brain delivery of selegiline loaded PLGA/lipid nanoparticles : Synthesis, characterisation and brain pharmacokinetics evaluation

Raman, Subashini and Khan, Arshad Ali and Mahmood, Syed (2022) Nose to brain delivery of selegiline loaded PLGA/lipid nanoparticles : Synthesis, characterisation and brain pharmacokinetics evaluation. Journal of Drug Delivery Science and Technology, 77 (103923). pp. 1-13. ISSN 1773-2247. (Published)

[img] Pdf
Nose to brain delivery of selegiline loaded PLGA.pdf
Restricted to Repository staff only

Download (5MB) | Request a copy
Nose to brain delivery of selegiline loaded PLGA_lipid nanoparticles_Synthesis, characterisation and brain pharmacokinetics evaluation_ABS.pdf

Download (263kB) | Preview


Parkinson's disease (PD) is the second most common progressive neurodegenerative disease that promotes neuronal cell death. The primary treatment strategy for Parkinson's disease involves the therapy of an MAO-B inhibitor molecule, selegiline. The present research aims to fabricate selegiline loaded polymeric (PLGA) nanoparticles (SPNPs) and selegiline loaded lipid-PLGA hybrid nanoparticles (SLPNPs) while using the single emulsion solvent evaporation method. The prepared SPNPs and SLPNPs formulations were subjected to preliminary optimisation using particle size, zeta-potential, and entrapment efficiency (EE%), and the selected formulations were subjected to further characterisation. Scanning electron microscopy (SEM) and high-resolution transmission electron microscopy (HRTEM) confirmed the particles' 2-D spherical morphology and size. ATR-FTIR was used to evaluate the physical interactions among the formulation ingredients. Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) studies confirm that SPNPs and SLPNPs were in an amorphous state. Ex-vivo studies showed 77.56% and 80% of drug permeation in 24 h for optimised formulations of SPNPs-2 and SLPNPs-1, respectively, while pure selegiline showed 65% Permeation. In-vivo study revealed a steady and controlled release profile with a half-life of 13.5 h, and AUC0-24 was observed at 130327.56 ± 231.6 ng/ml*h for SPNPs-2. For SLPNPs-1 an immediate release was observed with a very short half-life and AUC0-24 47548.57 ± 434.8 ng/ml*h compared with pure selegiline HCl solution with 2.3 h and AUC0-24 11116.52 ± 345.7 ng/ml*h. SLPNPs-1 has a shorter half-life due to its immediate release properties with the presence of lipid. Meanwhile, SPNPs-2, which only has a polymeric layer, has a longer half-life due to its sustained release properties. Overall, SPNPs-2 and SLPNPs-1 are promising carriers for selegiline nasal uptake and increase its brain bioavailability compared to oral absorption by pure selegiline.

Item Type: Article
Additional Information: Indexed by Scopus
Uncontrolled Keywords: Lipid-based formulation(s); Nasal drug delivery; Parkinson's disease; Poly(lactic-co-glycolic) acid (PLGA); Selegiline
Subjects: Q Science > QD Chemistry
T Technology > T Technology (General)
T Technology > TA Engineering (General). Civil engineering (General)
T Technology > TP Chemical technology
Faculty/Division: Institute of Postgraduate Studies
Faculty of Chemical and Process Engineering Technology
Depositing User: Mr Muhamad Firdaus Janih@Jaini
Date Deposited: 09 Feb 2024 01:53
Last Modified: 09 Feb 2024 01:53
Download Statistic: View Download Statistics

Actions (login required)

View Item View Item